Industry
Biotechnology
CalciMedica, Inc., a clinical-stage biotechnology company, focuses on developing therapies for life-threatening inflammatory diseases with unmet needs. Its proprietary technology targets the inhibition of calcium release-activated (CRAC) channels designs to modulate the immune response and protect against tissue cell injury in life-threatening inflammatory diseases. Its lead product candidate is Auxora, a proprietary intravenous-formulated CRAC channel inhibitor for the treatment of acute pancreatitis, asparaginase-associated acute pancreatitis, and acute kidney injury. The company is based in La Jolla, California.
Loading...
Open
3.38
Mkt cap
46M
Volume
37K
High
3.43
P/E Ratio
-19.88
52-wk high
8.38
Low
3.30
Div yield
N/A
52-wk low
2.68
Portfolio Pulse from Benzinga Newsdesk
October 30, 2024 | 9:13 pm
Portfolio Pulse from Benzinga Insights
October 30, 2024 | 4:31 pm
Portfolio Pulse from Benzinga Newsdesk
October 30, 2024 | 2:28 pm
Portfolio Pulse from Benzinga Insights
October 30, 2024 | 12:08 pm
Portfolio Pulse from Benzinga Insights
October 30, 2024 | 12:08 pm
Portfolio Pulse from Benzinga Newsdesk
October 30, 2024 | 11:22 am
Portfolio Pulse from Avi Kapoor
August 28, 2024 | 12:58 pm
Portfolio Pulse from Benzinga Newsdesk
August 13, 2024 | 6:05 pm
Portfolio Pulse from Benzinga Newsdesk
August 12, 2024 | 8:14 pm
Portfolio Pulse from Avi Kapoor
July 30, 2024 | 5:53 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.